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Ⅰ．Introduction
 Although many bile duct cancers are diagnosed 
at the icteric stage, with recent advances in medical 
modalities, such as multidetector-row computed 
tomography［1］, peroral cholangioscopy［2］, and 
intraductal ultrasonography［3］, more cases are being 
diagnosed at a non-icteric stage. Several case reports 
have been published［4-6］, but few involve non-icteric 
bile duct cancer cases obtained from a single institution
［7,8］. Because icterus and obstructive jaundice are 
known to develop with disease progression, prognosis 
is likely to improve with the diagnosis of patients at a 
non-icteric stage. Here, we examined and compared the 
clinicopathological features of icteric and non-icteric 
distal bile duct carcinoma patients at our institution over 
the past 10 years.
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SUMMARY
Many bile duct cancers are diagnosed at the icteric stage. However, with recent advances in 
medical modalities, patients are being diagnosed and treated at the non-icteric stage, which leads 
to better prognosis. In the past 10 years, we performed resections in 44 cases of distal bile duct 
carcinoma: 11 in non-icteric and 33 in icteric patients. We retrospectively examined and compared 
the clinicopathological features of icteric and non-icteric patients. The first symptoms of non-icteric 
patients were abdominal pain and pyrexia. In regard to hepatobiliary enzymes, increased gamma-
glutamyltransferase （GGT） levels appeared more frequently than the other enzymes evaluated. For the 
non-icteric and icteric groups, the overall survival rates 1, 3 and 5 years after surgery were 90.9% and 
72.7%; 90.9% and 42.5%; and 75.8% and 27.1%, respectively. The overall survival rate in non-icteric 
patients was significantly better than in icteric patients （P＜0.05）. Increased GGT level in patients 
without chronic hepatobiliary disease is an important component in the diagnosis of distal bile duct 
carcinoma at a non-icteric stage. 
　Key words:  distal bile duct carcinoma, non-icteric bile duct carcinoma, gamma-glutamyltransferase, early 
bile duct carcinoma
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Ⅱ．Material and Methods
Patients and methods
 From April 2003 to March 2013, we performed 
resections in 44 cases of distal bile duct carcinoma in 
Kimitsu Chuo Hospital: 11 cases were detected at a non-
icteric stage （serum total bilirubin level ≤  1.0 mg/dl） 
at the first visit to the medical institution, and 33 cases 
were detected at the icteric stage （serum total bilirubin 
＞1.0 mg/dl）. Distal bile duct carcinoma predominantly 
occurs at the lower half of the extra-hepatic bile duct, 
with most lesions situated below the confluence of 
the cystic duct. Japanese society of Hepato-Biliary-
Pancreatic Surgery defined distal bile duct carcinoma as 
occurring below the confluence of the cystic duct［9］. In 
this study, according to the American Joint Committee 
on Cancer （AJCC） cancer staging manual, the middle 
portion of the bile duct carcinomas were classified 
as their treatment, that is, a case with pancreatico- 
duodenectomy was treated as a distal one and a case 
with combined hepatic and hilar resection as a perihilar 
one［10］. 
 We retrospectively compared patient characteristics, 
such as, age, sex, tumor maker level （carcinoembryonic 
antigen ［CEA］ and carbohydrate antigen 19-9 ［CA19-
9］）, and operative methods. Chief complaints and 
laboratory data at the first visit to the medical institution 
were also examined. Final pathological reports were 
reviewed to confirm the diagnosis of distal bile 
duct carcinoma. The pathological findings, such as 
macroscopic tumor type, histological tumor type, degree 
of bile duct invasion, regional lymph node metastasis, 
pathological stage and operative curability were 
investigated. We compared the operative morbidity and 
mortality, including postoperative pancreatic fistula （PF）, 
delayed gastric emptying （DGE） and postoperative 
hepatic failure （HF）. The definition of PF was by the 
international study group of postoperative pancreatic 
fistula （ISGPF）［11］, DGE by the international study 
group of pancreatic surgery （ISGPS）［12］and HF by 
the international study group of liver surgery （ISGLS）
［13］. We also surveyed the patient’s overall survival rate 
according to operative curability, pathological stages, and 
the presence or absence of icterus at the first visit. The 
extent of the disease, including the classification of lymph 
node metastasis and pathological stages, was defined 
according to the 7th edition of the Union for International 
Cancer Control （UICC）, ICD-O C24.0. Operative 
curability was determined according to the currently used 
6th edition of Japanese General Rules for Clinical and 
Pathological Studies on Cancer of the Biliary Tract［9］. 
 Preoperative biliary drainage, endoscopically or 
percutaneously, was done in every cases except one in 
non-icteric group. In the non-icteric group, preoperative 
cholangiography revealed stenosis of the bile duct 
in some degree, so we drained all cases but one for 
prophylaxis of cholangitis.
 The reginal lymph nodes removal was done in all of 
the resected cases around the hepatoduodenal ligament, 
the common hepatic artery and head of the pancreas, 
and more, around the superior mesenteric artery in the 
cases of pancreaticoduodenectomy.
 
Statistical analysis
 The survival rate was calculated by the Kaplan-
Meier method, and statistical analysis was performed 
using the log-rank test. Chi-square or Fischer’s exact 
tests were used to compare qualitative parameters. P 
values of less than 0.05 were considered statistically 
significant.
Ⅲ．Results
 The median observation periods for the non-icteric 
and icteric groups were 56.4 months （0.9～117.7） 
and 23.9 months （0.8～132.1）, respectively. Although 
there were more male than female patients （27 : 6） in 
the icteric group, the patient gender ratio in non-icteric 
group was almost equivalent （6 : 5） （P＝0.108）. The 
patients’ ages were comparable in both groups. The 
median level of tumor markers （CEA, CA19-9） was 
within the normal range in the non-icteric group, but 
CA19-9 was slightly elevated in the icteric group. 
 We resected tumors by using pylorus-preserving 
pancreaticoduodenectomy （PpPD） in 34 patients, 
Whipple’s pancreaticoduodenectomy （PD） in 6 patients, 
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duodenum preserving pancreas head resection （DPPHR） 
in a patient in non-icteric group, and extra-hepatic 
bile duct resection in three patients in icteric group. 
DPPHR was done in a case of non-icteric group. She 
showed papillary tumor in the lower extrahepatic bile 
duct in preoperative cholangiography, and preoperative 
diagnosis was suspicion of carcinoma. Postoperative 
histological examination showed tumor was within 
mucosal layer with no lymph nodal metastasis, and 
histological curative resection （R0） was done. We 
resected bile duct only in three cases with the middle 
portion of extrahepatic bile duct carcinoma, because of 
age and poor general condition.
 All patients underwent dissection of the regional 
lymph nodes. The portal vein was resected en bloc 
in two patients in the icteric group owing to direct 
carcinoma invasion （Table 1）. Six patients in the icteric 
group received postoperative adjuvant chemotherapy, 
four with Tegafur/Gimeracil/Oteracil （S-1） and two 
with gemcitabine. Each two patients in the both group 
underwent post-operative irradiation owing to positive 
margins at the hepatic duct.
 The first symptoms in non-icteric bile duct 
carcinoma patients were abdominal pain in five patients 
and pyrexia in three. Although three patients presented 
with no clinical symptoms, one had abnormal hepatic 
function and two had dilatation of the intra/extrahepatic 
bile duct identified using abdominal ultrasonography. 
All of the icteric bile duct carcinoma patients first visited 
the medical clinic for icterus （Fig. 1）. In non-icteric 
patients, an increase in GGT appeared more frequently 
than other enzymes, such as aspartate aminotransferase 
（AST）, alanine aminotransferase （ALT）, lactate 
dehydrogenase （LDH）, alkaline phosphatase （ALP）. 
Levels ＞2 fold above the normal range were 18.2%, 
36.4%, 0%, 27.3%, and 63.6% for AST, ALT, LDH, 
ALP, and GGT, respectively. On the other hand, almost 
all of the hepatobiliary enzymes evaluated in the icteric 
patients showed abnormal levels, including serum total 
bilirubin （Fig. 2）. 
 One hospital death occurred in each group. One 
patient in the icteric group died 25 days after PpPD 
because of hepatic failure. He developed preoperative 
Fig. 1　 The first symptoms in patients with the distal bile 
duct carcinoma
　All of the icteric bile duct carcinoma patients first visited 
the medical clinic for icterus. Otherwise, in non-icteric 
patients, they visited the clinic for abdominal pain in five 
cases, pyrexia in three cases and three patients presented 
no clinical symptoms.
Table 1　Patients’ characteristics
Non-icteric （n＝11） Icteric （n＝33） P value
Sex （Male/Female） 6/5 27/6 n.s.
Age 70 （64－77） 72 （41－82） n.s.
CEA （ng/ml） 2.7 （1.3－7.7） 2.3 （0.9－6.3） n.s.
CA19-9 （U/ml） 19.7 （＜2－311） 53.4 （＜2－＞12000） n.s.
Operation method
（with en-bloc resection of portal vein） n.s.
     PD 1 （0） 5 （2）
     PPPD 9 （0） 25 （0）
     DPPHR 1 （0） 0 （0）
     Bile duct resection 0 （0） 3 （0）
Adjuvant chemotherapy 0 6 n.s.
Postoperative irradiation 2 2 n.s.
　CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, PD pancreaticoduodenectomy, PPPD 
pylorus preserving pancreaticoduodenectomy, DPPHR duodenum preserving pancreas head resection
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liver cirrhosis derived owing to hepatitis C virus 
infection, and postoperative uncontrollable ascites 
occurred. Another patient in the non-icteric group died 
26 days after PpPD because of aspiration pneumonia. 
He aspirated vomitus, which induced cardiopulmonary 
arrest on the 5th postoperative day. Grade B or C 
pancreatic fistula ［11］ occurred in 12 cases （36.4%） 
in the icteric group, and in 4 cases （36.4%） in the non-
icteric group, respectively; grade B or C delayed gastric 
emptying［12］occurred in 8 cases （24.2%） in the icteric 
group and in none of the cases in the non-icteric group. 
Other postoperative complications are listed in Table 
2. Overall morbidity was 60.6% in the icteric group 
and 45.5% in the non-icteric group （n.s.）. The median 
hospital stay was 33 （range 13-113） and 35 （16-139） 
days in the non-icteric and icteric groups, respectively. 
 Average tumor diameter in the non-icteric group 
was 28.0±15.0mm, and 33.6±18.5mm in the icteric 
group （n.s.）. With regards to macroscopic tumor type, 
papillary-expanding, papillary-infiltrating and nodular-
expanding types accounted for 54.5% of the tumors 
in the non-icteric group; nodular-infiltrating and flat-
infiltrating types accounted for 84.8% of the tumors in 
the icteric group. Regarding the histological tumor type, 
papillary adenocarcinoma （pap） and well-differentiated 
tubular adenocarcinoma （tub1） accounted for 90.9% of 
the tumors in the non-icteric group; poorly differentiated 
adenocarcinoma （por） and moderately differentiated 
tubular adenocarcinoma （tub2） accounted for 66.6% 
of the tumors in the icteric group. One patient in the 
icteric group had an adenosquamous carcinoma of the 
bile duct. The depth of bile duct wall invasion at the 
level of T1 or T2 accounted for 90.9% of the cases in 
the non-icteric group; Moreover, 72.7% of the cases 
in icteric group were over T3, and 81.8% of the non-
icteric patients had no regional lymph node metastasis. 
In contrast, 54.5% of the icteric bile duct carcinoma 
patients exhibited metastasis to regional lymph nodes. 
In terms of pathological stage, 72.7% were under Stage 
IB in the non-icteric group, whereas 78.8% were over 
Stage IIA in the icteric group （Table 3）.
 With regards to overall survival, Stage IA patients 
had significantly better prognoses than Stage IIA 
（P＜0.05） and IIB （P＜0.01） patients （Fig. 3）. 
Fig. 2　 Hepatobiliary enzyme profiles of the distal bile 
duct patients at the first visit to the medical 
institute
　（a） In non-icteric patients, GGT increased more 
frequently than other enzymes, such as AST, ALT, LDH 
and ALP. （b） In icteric patients, the majority of the 
hepatobiliary enzymes showed abnormal levels, including 
serum total bilirubin.
　GGT gamma-glutamyltransferase, AST aspartate 
aminotransferase, ALT alanine aminotransferase, LDH 
lactate dehydrogenase, ALP alkaline phosphatase.
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Table 2　Postoperative morbidity and mortality
Non-icteric （n＝11） Icteric （n＝33） P value
Grade B, C pancreatic fistula 4 （36.4%） 12 （36.4%） 1.000
Grade B, C delayed gastric emptying 0 （0%） 8 （24.2%） 0.071
Postoperative bleeding 0 （0%） 2 （6.1%） 0.403
Wound insufficiency 0 （0%） 2 （6.1%） 0.403
Anastomosis insufficiency 0 （0%） 1 （3.0%） 0.559
Chylorrhea 0 （0%） 1 （3.0%） 0.559
Ascites 0 （0%） 1 （3.0%） 0.559
Hepatic failure 0 （0%） 1 （3.0%） 0.559
Brain infarction 0 （0%） 1 （3.0%） 0.559
Aspiration pneumonia 0 （0%） 1 （3.0%） 0.559
Other 1 （9.1%） 1 （3.0%） 0.559
Overall morbidity 5 （45.5%） 20 （60.6%） 0.268
Mortality 1 （9.1%） 1 （3.0%） 0.403
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Histologically curative surgery （R0） was performed 
in 63.6% and 45.5% of the patients in the non-icteric 
and icteric groups, respectively （Table 3）. The R0 
group showed significantly better prognosis than the 
non-curative group （R1, R1cis, R2） （P＜0.01） （Fig. 
4）. The overall survival rates 1, 3, and 5 years after 
surgery were 90.9% and 72.7%, 90.9% and 42.5%, and 
75.8% and 27.1% in the non-icteric and icteric groups, 
respectively. The overall survival rate in patients who 
underwent resection for non-icteric distal bile duct 
carcinoma was significantly better than that in icteric 
patients （P＜0.05） （Fig. 5）.
Table 3　Pathological findings
Non-icteric Icteric P value
（n＝11） （n＝33）
Maximum tumor diameter （mm）
（average±S.D.）
28.0±15.0 33.6±18.5 0.373
Macroscopic type 0.022
Papillary-expanding 3 （27.3%） 1 （3.0%）
Papillary-infiltrating 1 （9.1%） 4 （12.1%）
Nodular-expanding 2 （18.2%） 0
Nodular-infiltrating 3 （27.3%） 14 （42.4%）
Flat-infiltrating 2 （18.2%） 14 （42.4%）
Histological type ＜0.001
pap 3 （27.3%） 1 （3.0%）
tub1 7 （63.6%） 9 （27.3%）
tub2 1 （9.1%） 18 （54.5%）
por 0 4 （12.1%）
other 0 1 （3.0%）
T classiﬁcation ＜0.001
T1 6 （54.5%） 2 （6.1%）
T2 4 （36.4%） 7 （21.2%）
T3 1 （9.1%） 24 （72.7%）
T4 0 0
Regional lymph none 0.038
N0 9 （81.8%） 15 （45.5%）
N1 2 （18.2%） 18 （54.5%）
Stage 0.002
IA 6 （54.5%） 2 （6.1%）
IB 2 （18.2%） 5 （15.2%）
IIA 1 （9.1%） 8 （24.2%）
IIB 2 （18.2%） 17 （51.5%）
III 0 0
IV 0 1 （3.0%）
Curability 0.127
R0 7 （63.6%） 15 （45.5%）
R1cis 2 （18.2%） 1 （3.0%）
R1 2 （18.2%） 16 （48.5%）
R2 0 1 （3.0%）
　pap papillary adenocarcinoma, tub1  well-differentiated tubular adenocarcinoma, tub2  moderately differentiated 
tubular adenocarcinoma, por poorly differentiated adenocarcinoma, R0  no residual carcinoma, R1  carcinoma 
remained histologically (histologically positive for resected margin), R1cis R1 with superficial spreading, R2  
carcinoma remained macroscopically.
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Fig. 3　Overall survival according to the pathological stage
　Stage IA patients exhibited significantly better prognosis 
than Stage IIA （P＜0.05） and Stage IIB （P＜0.01） 
patients.
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carcinomas［16,17］On the other hand, there is no 
clear definition of early bile duct carcinoma, although 
some authors advocate defining “the early bile duct 
carcinoma” as a lesion in which the depth of wall 
invasion is within the fibro-muscular layer, and report its 
favorable prognosis ［3, 18-20］.
 Most bile duct carcinoma patients visit medical 
institutions for icterus. Distal bile duct carcinoma often 
requires PD or PpPD for curative resection－operative 
procedures that have high morbidity and mortality
［21,22］. Even if a clinically curative operation is 
performed, it is difficult to obtain histological negative 
margins［23］. 
 Icterus inevitably appears in distal bile duct carcinoma 
with progression of the disease, whereas in perihilar 
bile duct carcinoma, icterus does not appear until the 
tumor invades the confluence. Consequently, icterus may 
appear somewhat earlier in distal bile duct carcinoma 
than in perihilar carcinoma. If distal bile duct carcinoma 
is diagnosed earlier, at a non-icteric stage, the prognosis 
is better. As the levels of two tumor markers, CEA and 
CA19-9, were within the normal range in the majority 
of the non-icteric bile duct patients evaluated, they 
contributed little to a meaningful diagnosis.
 GGT is a membrane-bound enzyme that exists in 
several tissues, such as the kidney, pancreas, and liver, 
and plays a role in the metabolism of glutathione and in 
the facilitation of amino acid transport. It is known that 
serum GGT levels increase in hepatobiliary disease－
especially alcoholic liver disease and cholestasis－
but not in renal disease. GGT is synthetized in the 
endoplasmic reticulum of hepatocytes and is then 
released and localized in the membranes of the bile 
canaliculi in the liver, or in the epithelium of the bile 
duct［24］. In Korean report, among the medical records 
of 2024 subjects who attended the institution for medical 
check-up, 78 subjects were a positive for hepatitis C 
virus antibody and/or hepatitis B virus surface antigen 
and/or liver cirrhosis, 579 subjects were a daily alcohol 
intake of 20g or more. In the rest of 1367 subjects, 352 
subjects （25.7%） showed abnormal hepatic enzyme/
GGT, 10 subjects were with incomplete data. Among the 
rest of 1005 subjects, serum alanine aminotransferase 
Ⅳ．Discussion
 Early gastric or colorectal cancers are defined as 
lesions in which the depth of wall invasion is within the 
submucosal layer, regardless of lymph node metastasis
［14,15］. These early carcinomas show comparably 
better prognoses than those that are more advanced. 
Screening gastro fiberscope or fecal occult blood 
tests have contributed to improved detection of these 
Fig. 4　Overall survival according to the curability
　Patients in the histologically curative operation （R0） 
group （grey line） showed significantly better prognosis 
than those in the non-curative group （R1, R1cis, R2） 
（black line; P＜0.01）.
　R0  no residual carcinoma, R1  carcinoma remained 
histologically （histologically positive for resected margin）, 
R1 cis R1 with superficial spreading, R2  carcinoma 
remained macroscopically.
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Fig. 5　 Overall survival of the distal bile duct carcinoma 
patients between non-icteric and icteric patients
　Overall survival rates 1, 3 and 5 years after surgery were 
90.9% and 72.7%; 90.9% and 42.5%; and 75.8% and 
27.1% in the non-icteric and icteric groups, respectively. 
The overall survival rate of the resected patients with 
non-icteric distal bile duct carcinoma （grey line） was 
significantly better than that of icteric patients （black line; 
P＜0.05）.
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（72.7%）; （4） regional lymph node metastasis （54.5% of 
patients）; and （5） pathological stage greater than Stage 
II disease （78.8% of patients）. Although Sugiyama et 
al. and Ito et al. reported that there were no significant 
differences in the pathological findings between non-
icteric and icteric patients［7,8］, there were obvious 
differences between these patient groups in our study. A 
reason for this may be that almost half of the cases （40-
89%） in the previous studies were proximal bile duct 
carcinomas, making it possible that more advanced cases 
were included in the non-icteric groups. 
 The R0 resection rate was 63.6% in the non-icteric 
group and 45.5% in the icteric group; the overall 
curative resection rate was 50.0%, which is comparable 
to previously reported cases （30.4%-68.1%）［21,23］. 
Even in the non-icteric group, the curative resection 
rate was somewhat low （63.6%）, probably because 
of histologically positive margins at the surgical site in 
four patients （36.4%）, two of whom （18.2%） showed 
superficial mucosal spreading of carcinoma. It is well 
known that the intraductal papillary growth of bile duct 
carcinoma is likely to spread widely and superficially
［26］. The curative operation group showed significantly 
better prognosis than the non-curative group （P＜0.01）, 
emphasizing the importance of a negative margin during 
the surgical procedure.
 The overall survival rate of resected patients with 
non-icteric distal bile duct carcinoma was significantly 
better than that of icteric patients （P＜0.05）. Sugiyama 
et al. also reported significantly higher survival rates in 
non-icteric patients compared with icteric patients （50% 
vs. 22% at 5 years）［7］. Relatively better prognosis in 
non-icteric bile duct carcinoma is thought to be related 
to early stage, well-differentiated carcinoma and less 
regional lymph node metastasis. Because of the soft 
pancreas, the rates of grade B and C postoperative 
pancreatic fistula were higher in this study compared to 
those reported in other cases, but were equivalent in both 
groups. The overall morbidity rate was lower in the non-
icteric than icteric group （45.5% vs. 60.6%）, but not 
significant. Two hospital deaths occurred in this study; 
this 4.5% （2/44） death rate is similar to that reported 
in the Japanese national web-based data of extrahepatic 
（ALT） and GGT concentration within the reference 
ranges correlated with the incidence of nonalcoholic 
fatty liver disease （NAFLD） and metabolic syndrome 
in a dose-dependent manner［25］.
 Serum bilirubin levels increase in obstructive 
jaundice, but not in the case of partial obstruction of 
the bile duct. Thus, in the case of perihilar bile duct 
carcinoma, obstruction of unilateral hepatic ducts, i.e., 
either the right or left hepatic duct, does not lead to 
increased serum bilirubin levels until the tumor has 
invaded the confluence. Sugiyama et al. have reported 
cases of extrahepatic bile duct carcinoma without 
jaundice, but most of these lesions （89%） were in the 
upper third of the extrahepatic bile duct［7］. Ito et al. 
also reported clinicopathological features of extrahepatic 
cholangiocarcinoma without jaundice, and 40% of 
these were perihilar lesions［8］. Thus, in these reports, 
carcinomas that were not associated with jaundice were 
mainly located in the upper bile duct.
 On the other hand, ALP or GGT levels increase 
even in the case of hemi obstruction. In this study, GGT 
increased more frequently than the other hepatobiliary 
enzymes evaluated in the patients without jaundice. 
GGT is thought to be the most sensitive hepatocyte-
released enzyme marker of bile duct compression. 
 In this study, non-icteric bile duct carcinoma 
was characterized by: （1） macroscopic tumor types 
consisting of papillary-expanding, papillary-infiltrating, 
and nodular-expanding tumors （54.5%）; （2） histological 
tumor types comprising papillary adenocarcinoma and 
well-differentiated tubular adenocarcinoma （90.9%）; 
（3） depth of bile duct wall invasion at level T1 or 
T2 （90.9%）; （4） no regional lymph node metastasis 
（81.8% of patients）; and （5） pathological stages IA 
and IB （72.7% of the cases）, indicating that non-icteric 
patients do not always have early-stage tumors. On the 
contrary, the icteric bile duct carcinoma cases in this 
study were characterized by: （1） macroscopic tumor 
types consisting of nodular-infiltrating type and flat-
infiltrating type tumors （84.8%）; （2） histological tumor 
types comprising poorly differentiated adenocarcinoma 
and moderately differentiated tubular adenocarcinoma 
（66.6%）; （3） depth of bile duct wall invasion over T3 
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bile duct carcinoma［22］. In terms of prognosis and 
operative morbidity, it is critical that we diagnose and 
treat distal bile duct carcinoma patients at a non-icteric 
stage. 
 Therefore, here we emphasize the importance of 
the increase in GGT levels in patients without chronic 
liver disease, for example, those with chronic hepatitis, 
alcoholic liver disease, or nonalcoholic fatty liver disease, 
as a tool in diagnosing distal bile duct carcinoma at a 
non-icteric stage.
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